Add Yahoo as a preferred source to see more of our stories on Google. KINGSPORT, Tenn. (WJHL) – On Wednesday, Holston Valley Medical Center (HVMC) successfully performed a cardiac ablation procedure ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Boston Scientific's FARADISE registry study is due to run for another two years before its completion in 2027. Image credit: Mehaniq via Shutterstock.com. · Medical Device Network · Mehaniq via ...
Narrow-moat Boston Scientific’s BSX long-awaited clinical data on its Farapulse pulsed field ablation, or PFA, device for atrial fibrillation didn’t disappoint, and we’ve raised our fair value ...
Octane is launching the Mussallem Cardiovascular Accelerator for breakthrough diagnosis, treatment, monitoring, and patient ...
In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line ...
SAN DIEGO, Calif. (Ivanhoe Newswire) - Atrial fibrillation, or AFib is the most common type of heart arrhythmia. It’s estimated 12 million people in the U.S. are living with it. If not treated, it can ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Allan Zingeler, Raju Viswanathan, PhD, and Michael Mahoney of Boston Scientific have been awarded the inaugural Thomas J. Fogarty Prize (Fogarty Prize) for the ...
Dr. Steven Mickelsen dreamed up a new way to treat a heart condition called atrial fibrillation while finishing a medical fellowship at the University of Iowa in 2012. His idea of using pulsed ...
Boston Scientific, Inc. BSX recently gained the FDA’s approval for the FARAPULSE Pulsed Field Ablation (“PFA”) system, which is indicated for the isolation of pulmonary veins in the treatment of ...
MARLBOROUGH, Mass. and AMSTERDAM, Aug. 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal ADVENT clinical trial of the ...
Editor's note: This is the first of a two-part series on the Boston Scientific Investor Day presentation. This first part focuses on the company's Farapulse pulsed field ablation system. Part two will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results